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Background: The maximum standardized uptake value (SUVmax) is a common clinical parameter for quantification
in F18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), but it is influenced
by image reconstruction. The aim of this study was to analyze the association of SUVmax deviations related to point
spread function (PSF) and time-of-flight (TOF) reconstruction with tumor-to-background ratios (TBR) in colorectal
liver metastases (CRLM).
Methods: Fifteen patients (f, 6; m, 9; median age, 59 years; range, 32 to 72 years) with 28 liver metastases were
included retrospectively. FDG-PET/CT imaging (median activity, 237 MBq; range, 231 to 252 MBq; median uptake,
61 min; range, 55 to 67 min) was performed on a Siemens Biograph mCT 64 followed by image reconstruction
using 3D-ordered subset expectation maximization (3D-OSEM) or 3D-OSEM with PSF modeling - both with and
without TOF information. Differences in SUVmax were analyzed using the Friedman test and Wilcoxon test for
paired non-parametric data. The correlation of inter-method differences with the lesions’ TBR was studied using
Spearman’s rank correlation coefficient (rho). Differences between lesions with low (<4.8) and high (>4.8) TBR were
analyzed using the Mann-Whitney U test (TBR measured with 3D-OSEM; binarized by its median).
Results: There was a significant correlation of the lesions’ TBR with relative SUVmax differences related to PSF (PSF +
TOF vs. 3D-OSEM + TOF, rho = 0.61; PSF vs. 3D-OSEM, rho = 0.52) or TOF (PSF + TOF vs. PSF, rho = −0.58; 3D-OSEM+
TOF vs. 3D-OSEM, rho = −0.61). Accordingly, PSF algorithms only showed higher SUVmax than non-PSF algorithms in
lesions with a high TBR (median differences at low/high TBR, +2.6%/+9.1% [PSF + TOF vs. 3D-OSEM+ TOF]; +0.7%/+6.4%
[PSF vs. 3D-OSEM]). TOF integration also led to higher SUVmax but mainly at low TBR (low/high TBR, +10.4%/+1.8%
[PSF + TOF vs. PSF]; +8.6%/−0.1% [3D-OSEM+ TOF vs. 3D-OSEM]).
Conclusions: Both PSF and TOF reconstruction resulted in a substantial alteration of SUVmax in CRLM. TOF provided
the highest SUVmax increase in low-contrast lesions while - vice versa - PSF showed the most relevant increase in
high-contrast lesions. Thus, one should be aware that quantitative analyses of lesions with varying TBR, e.g., in
radiotherapy or follow-up studies, may be mainly affected by either PSF or TOF reconstruction, respectively.
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Combined F18-fluorodeoxyglucose positron emission
tomography/computed tomography (FDG-PET/CT) has
proven its significant impact on the therapeutic manage-
ment in patients with colorectal liver metastases (CRLM)
when compared to conventional imaging methods, such
as CT or magnetic resonance imaging (MRI) [1-4]. More-
over, the maximum standardized uptake value (SUVmax)
as a common quantitative measure of the focal FDG up-
take may be helpful for therapy response assessment [5] or
as a basis for target volume definition in radiotherapy
planning [6,7].
However, FDG-PET quantification is influenced by the
reconstruction algorithm used [8,9]. Recent algorithms
feature iterative calculations with integration of time-of-
flight (TOF) analysis (to approximate the real location of
the positron-electron annihilation) and the point spread
functions (PSF) of the PET scanner to account for its
specific detection properties. Prieto et al. [10] and
Knäusl et al. [11,12] reported higher SUV and smaller
metabolic tumor volumes (MTV) when applying these
algorithms compared to common ordered subset expect-
ation maximization (OSEM) algorithms. Accordingly,
they should be used with caution for the purpose of
quantification. Although a reliable reference value is
missing in clinical lesions, the assumed SUVmax over-
estimation by PSF-based algorithms could result in a dis-
torted assessment of therapy response or inaccurate
volume definition.
In a recent publication, we showed based on phantom
measurements that the mentioned inter-method differ-
ences depend on the respective signal-to-background ratio
(SBR) and are nearly absent at low SBR which are typical
for hepatic lesions [13]. Furthermore, an independent
evaluation of TOF-related effects on quantification in liver
lesions has not been performed so far. Thus, the aim of
the present study was to evaluate the influence of PSF and
TOF reconstruction and tumor-to-background ratios
(TBR) on SUVmax in patients with CRLM.
Methods
Patients
This retrospective, explorative single-center study in-
cluded 15 patients [female, n = 6; male, n = 9; median
age, 59 years (range, 32 to 72 years)] which had been re-
ferred for FDG-PET/CT in our department to evaluate
potential palliative treatment options including systemic
chemotherapy and/or local ablative therapy. All patients
suffered from FDG-avid liver metastases from colorectal
cancer (rectal cancer, n = 9; colon cancer, n = 6), and all
patients had undergone at least one line of systemic
chemotherapy (median, two lines; range, one to five
lines). Written informed consent of the patients was ob-
tained for the publication of this report and anyaccompanying images. This analysis was performed in
compliance with the Helsinki Declaration and approved
by the ethics commission of the Otto-von-Guericke
University Magdeburg (ID number: RAD196).
PET/CT
PET/CT imaging was performed using the tracer F18-
FDG and a dedicated PET/CT device (Biograph mCT
64®; Siemens Healthcare, Erlangen, Germany) according
to procedure guidelines for tumor PET imaging by the
European Association of Nuclear Medicine [14]. Whole-
body imaging was performed from the vertex to the
proximal femora within six to eight bed positions (emis-
sion, 3 min each) and axial bed coverage of 216 mm
each (Siemens TrueV®; bed overlap, 89 mm). A median
activity of 237 MBq (range, 231 to 252 MBq) was ap-
plied intravenously with a median uptake time of 61 min
(range, 55 to 67 min). A low-dose CT was used for at-
tenuation correction and anatomical mapping (50 mA,
120 kV, 0.5 s/rotation; pitch, 0.8).
Image reconstruction
FDG-PET raw data were reconstructed with four algo-
rithms and respective presets provided by the manufac-
turer: 3D-ordered subset expectation maximization
(3D-OSEM; iterations, 2; subsets, 24), 3D-OSEM +
time-of-flight analysis (3D-OSEM + TOF; iterations, 2;
subsets, 21), iterative reconstruction with system-
specific PSF modeling (PSF; Siemens TrueX®, ‘HD∙PET’;
iterations, 2; subsets, 24), and PSF + TOF (Siemens
‘ultraHD∙PET’; iterations, 2; subsets, 21) [15]. The pro-
jection data were reconstructed with 3-mm slice thickness
(rows, 200; columns, 200; voxel size, 4.1 × 4.1 × 3.0 mm).
After reconstruction, a Gaussian filter (FWHM, 2 mm)
was applied to all data. Attenuation correction CT raw
data were reconstructed with a slice thickness of 3 mm
and a filter for abdominal low-dose CT (convolution
kernel, B30f ).
SUV and TBR
All SUV were measured using dedicated software
(ROVER, version 2.1.4, ABX advanced biochemical com-
pounds GmbH, Radeberg, Germany). The TBR was de-
fined as the ratio of the lesions’ SUVmax and the
SUVmean of healthy liver tissue (background) determined
for each reconstruction algorithm. The background SUV-
mean was measured within a spherical volume of interest
(diameter, 50 mm) positioned in an area of physiological
liver tissue.
Dedicated CECT and MRI
The morphological lesion volume (expressed in ml) was
measured in MRI data if available (seven patients) or in
contrast-enhanced CT (CECT) data (eight patients) by
Table 1 SUVmax and TBR for each reconstruction
algorithm
PSF + TOF PSF 3D-OSEM + TOF 3D-OSEM
SUVmax
Median 12.2 11.0 11.6 11.1
IQR 10.5 to 17.4 9.3 to 17.2 9.9 to 16.0 9.4 to 16.8
Range 5.5 to 47.1 4.4 to 47.5 5.3 to 42.6 4.8 to 43.8
TBR
Median 5.0 4.7 4.6 4.8
IQR 3.3 to 6.3 3.2 to 6.1 3.4 to 5.8 3.1 to 5.6
Range 1.8 to 16.9 1.7 to 16.5 1.9 to 15.3 1.8 to 15.3
Median values of SUVmax and TBR displayed for all reconstruction algorithms
with their respective IQR and range.
Table 2 Relative SUVmax differences - PSF vs. non-PSF
Difference PSF + TOF vs. 3D-OSEM + TOF PSF vs. 3D-OSEM
Low TBR High TBR Low TBR High TBR
n.s. ** n.s. **
Median 2.6 9.1 0.7 6.4
IQR −1.2 to 5.0 6.0 to 15.2 −4.0 to 3.4 0.9 to 12.9
Range −5.3 to 14.2 −1.6 to 23.7 −10.1 to 9.8 −4.7 to 24.8
Median, IQR, and range of relative SUVmax differences between PSF and non-
PSF algorithms displayed separately for low (<4.8) and high (>4.8) TBR. Wil-
coxon test: n.s., not significant; **P < 0.01.
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MRI was performed within 8 weeks of the FDG-PET/CT
examination (median, 1 day; IQR, 0 to 14 days; range, 0
to 48 days). CECT data were acquired 70 s after intra-
venous injection of 80 to 150 ml of a non-ionic iodin-
ated contrast agent (Imeron 300, iomeprol 300, Bracco
ALTANA Pharma GmbH, Konstanz, Germany). CT
scans were performed from the apex of the lungs to the
thigh (automatic tube current modulation with max-
imum tube current, 230 mAs; tube voltage, 120 kV; gan-
try rotation, 0.5 s). MRI of the liver was performed using
a 1.5-T Philips Acheiva® (Philips, Best, The Netherlands)
in enhanced T1 High Resolution Isotropic Volume Excita-
tion (eTHRIVE) mode after intravenous administration of
0.025 mmol/kg bodyweight Gd-EOB-DTPA (Primovist®,
Bayer, Leverkusen, Germany).
Statistical analysis
Data analyses were carried out using SPSS 22 (IBM
Corporation, Armonk, NY, USA) and R 3.1.3 (Foundation
for Statistical Computing, Vienna, Austria, 2015, http://
www.R-project.org). Due to a small sample size, non-
parametric distribution of data was assumed. Descriptive
parameters were expressed as median, interquartile range
(IQR), and range and depicted as box plots. SUVmax dif-
ferences between reconstruction algorithms were investi-
gated using the Friedman test and Wilcoxon signed-rank
test for paired non-parametric data. The correlation be-
tween relative SUVmax differences and the lesions’ TBR
was analyzed using the Spearman’s rank correlation coeffi-
cient. Furthermore, a binarization of the measured TBR
was performed based on its median value measured in
3D-OSEM reconstructed data (<4.8/>4.8) followed by the
Mann-Whitney U test to compare SUVmax differences
in lesions classified by low and high TBR, respectively.
Similarly, the lesion volumes were binarized by the me-
dian value (9.3 ml) to compare small and large lesions.
General linear models (GLM) including the TBR mea-
sured in 3D-OSEM reconstructed data, the lesion vol-
ume, and their interaction (TBR * lesion volume) were
calculated to examine the association of both variables
with the SUVmax differences. Corresponding inter-
action plots based on binarized TBR and lesion volume
were created. Statistical significance was assumed at a
P value of less than 0.05.
Results
Twenty-eight FDG-avid hepatic target lesions were ana-
lyzed. The median background SUVmean was similar
for all reconstruction algorithms (median SUVmean, 2.8;
range, 2.0 to 4.1). The measured SUVmax and calculated
TBR are summarized in Table 1. Inter-method SUVmax
differences and their correlation with the TBR were
assessed separately for PSF and TOF. Accordingly, thefollowing section provides a comparison of correspond-
ing PSF and non-PSF algorithms (PSF + TOF vs. 3D-
OSEM+ TOF; PSF vs. 3D-OSEM) or corresponding
TOF and non-TOF algorithms (PSF + TOF vs. PSF; 3D-
OSEM+ TOF vs. 3D-OSEM), respectively.
SUVmax differences between PSF and non-PSF algorithms
In lesions with low TBR (<4.8), PSF + TOF provided
comparable SUVmax as 3D-OSEM +TOF (median dif-
ference, +2.6%; P = 0.1). PSF featured similar SUVmax as
3D-OSEM (+0.7%; P = 0.73). In lesions with high TBR
(>4.8), PSF + TOF showed significantly higher SUVmax
than 3D-OSEM+ TOF (median difference, +9.1%; P <
0.01). PSF also provided higher SUVmax than 3D-
OSEM (+6.4%; P < 0.01).
The inter-method differences for PSF + TOF vs. 3D-
OSEM+TOF and PSF vs. 3D-OSEM were significantly
higher in high-contrast lesions compared to low-contrast
lesions (Mann-Whitney U test; each P < 0.05). All differ-
ences are also displayed in Table 2, while Figure 1 displays
corresponding box plots. Figure 2 provides axial PET im-
ages of representative examples to illustrate the effect of
the TBR on the extent of PSF-related SUVmax differences.
SUVmax differences between TOF and non-TOF algorithms
In lesions with low TBR (<4.8), PSF + TOF provided sig-
nificantly higher SUVmax in comparison with PSF
Figure 1 Relative SUVmax differences between reconstruction algorithms. Box plots of relative SUVmax differences in lesions with low TBR and
high TBR. Comparison of PSF vs. non-PSF (upper row) as well as TOF vs. non-TOF algorithms (lower row). Outliers are marked as circles.
Figure 2 Representative examples of lesions with high and low TBR. This figure displays the axial FDG-PET images (jet color table) of a lesion with
high TBR (A; TBR, 11.4; volume, 10.0 ml) and a lesion with low TBR (B; TBR, 3.6; volume, 7.9 ml) for all analyzed reconstruction algorithms. The
windowing level was the same for all differently reconstructed data (but different between A and B). At high contrast (A), the SUVmax is mainly
increased by PSF integration (+22% and +25%) and marginally affected by TOF (+0.2% and +2%). At low contrast (B), the opposite is true
(PSF, +3% and +4%; TOF, +15% and +16%).
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Table 4 Correlation between relative SUVmax differences
and the TBR
vs. PSF 3D-OSEM+ TOF 3D-OSEM
PSF + TOF ρ = −0.58 ρ = 0.6 ρ = −0.23
P = 0.002 P = 0.001 P = 0.269
PSF – ρ = 0.68 ρ = 0.52
P < 0.001 P = 0.006
3D-OSEM + TOF – – ρ = −0.61
P = 0.001
Spearman’s rho (ρ) and degree of significance for the correlation of relative
SUVmax differences related to PSF or TOF with the lesions’ TBR. Significant
results are printed in italics.
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also featured higher SUVmax than 3D-OSEM (+8.6%; P <
0.01). In lesions with high TBR (>4.8), PSF + TOF showed
comparable SUVmax in comparison with PSF (median
difference, +1.8%; P = 0.2). 3D-OSEM+TOF featured
similar SUVmax as 3D-OSEM (−0.1%; P = 0.73).
The SUVmax differences for PSF + TOF vs. PSF and
3D-OSEM+TOF vs. 3D-OSEM were significantly higher
at low TBR compared to high TBR (each P < 0.01). All dif-
ferences are also displayed in Table 3. Figure 1 provides
corresponding box plots and Figure 2 illustrates represen-
tative examples.
Correlation of relative SUVmax differences with the TBR
The relative SUVmax differences between PSF + TOF
and 3D-OSEM+ TOF were positively correlated with
the lesions’ TBR measured for 3D-OSEM (ρ = 0.6; P <
0.01). Differences between PSF and 3D-OSEM also
showed a significant positive correlation with the re-
spective TBR (ρ = 0.52; P < 0.01).
Conversely, the relative SUVmax differences between
PSF + TOF and PSF were negatively correlated with the
lesions’ TBR (ρ = −0.58; P < 0.01). Differences between
3D-OSEM+ TOF and 3D-OSEM featured a negative
correlation (ρ = −0.61; P < 0.01) with the TBR, too
(Table 4, Figure 3). There was no significant correlation
of SUVmax differences between PSF + TOF and 3D-
OSEM with the TBR (ρ = −0.23; P = 0.269).
Dependency of relative SUVmax differences on the
lesion volume
The lesion volume measured in CECT or MRI data
ranged from 0.8 to 60.3 ml (median, 9.3 ml; IQR, 2.8 to
29.3 ml). There was a significant positive correlation of
the lesion volume and the TBR measured in 3D-OSEM
reconstructed data (ρ = 0.56; P < 0.01). Lesions with a
high TBR were significantly larger (median, 18.5 ml;
IQR, 8.1 to 45.1 ml) than lesions with low TBR (median,
3.7 ml; IQR, 2.1 to 14.1 ml; P < 0.01).
There was no significant correlation between PSF-
related SUVmax differences and the lesion volume (PSF +
TOF vs. 3D-OSEM+TOF, ρ = 0.03; P = 0.88; PSF vs. 3D-
OSEM, ρ = 0.08; P = 0.68). SUVmax differences betweenTable 3 Relative SUVmax differences - TOF vs. non-TOF
Difference PSF + TOF vs. PSF 3D-OSEM+ TOF vs. 3D-OSEM
Low TBR High TBR Low TBR High TBR
** n.s. ** n.s.
Median 10.4 1.8 8.6 −0.1
IQR 3.1 to 19.0 −0.8 to 5.5 3.3 to 14.8 −6.0 to 2.4
Range 1.0 to 27.2 −16.7 to 27.9 −5.9 to 17.5 −13.9 to 24.0
Median, IQR, and range of relative SUVmax differences between TOF and
non-TOF algorithms displayed separately for low (<4.8) and high (>4.8) TBR.
Wilcoxon test: n.s., not significant; **P < 0.01.TOF and non-TOF algorithms showed a significant nega-
tive correlation with the lesion volume (PSF + TOF vs.
PSF, ρ = −0.5; P < 0.01; 3D-OSEM+TOF vs. 3D-OSEM,
ρ = −0.41; P < 0.05). Neither PSF-related nor TOF-related
SUVmax differences varied significantly between small
and large lesions (each P > 0.05).
The GLM showed a significant association of SUVmax
differences between PSF and non-PSF algorithms with
the TBR (PSF + TOF vs. 3D-OSEM +TOF, P < 0.001;
PSF vs. 3D-OSEM, P < 0.001) but not with the lesion
volume (both P = 0.91). The interaction between the
TBR and lesion volume was significant (both P < 0.05;
Figure 4). TOF-related SUVmax differences were associ-
ated with the TBR (PSF + TOF vs. PSF, P < 0.05) or
showed a tendency towards an association (3D-OSEM +
TOF vs. 3D-OSEM, P = 0.054). There was no significant
association with the lesion volume (P = 0.2 and P = 0.18).
The interaction between TBR and lesion volume was
also not significant (both P > 0.15; Figure 4).
Discussion
The present study focused on SUVmax in patients with
CRLM, examining the influence of PSF and TOF recon-
struction algorithms as well as different TBR.
The integration of PSF and TOF into reconstruction
revealed relevant impact on SUVmax when lesions were
separated by their TBR (low, <4.8; high, >4.8) measured
in 3D-OSEM reconstructed data. In lesions with a high
TBR, both PSF + TOF and PSF showed significantly
higher SUVmax compared to the corresponding non-
PSF algorithms. The median relative differences were
slightly higher for combined PSF + TOF (PSF + TOF vs.
3D-OSEM+ TOF, +9.1%) than for PSF alone (PSF vs.
3D-OSEM, +6.4%). Of course, these results are, strictly
speaking, only valid for the specific scanner and recon-
struction software used in this study, but it can be ex-
pected that with other systems, similar SUV deviations
would occur.
Knäusl et al. evaluated nine lung lesions regarding
SUVmax based on PSF (also Siemens TrueX® algorithm)
and OSEM reconstruction and reported even higher
Figure 3 Correlation of relative SUVmax differences with the TBR. Correlation plots of relative SUVmax differences and the lesions’ TBR between
corresponding PSF and non-PSF algorithms (upper row) or TOF and non-TOF algorithms (lower row), respectively. The solid and dashed lines
represent mean ± two standard deviations.
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typically higher TBR in pulmonary lesions with pro-
nounced SUV differences and due to an increased noise
level caused by the higher product of iterations and sub-
sets used by Knäusl et al. (4 iterations, 21 subsets).
Akamatsu et al. analyzed 41 lymph node metastases and
observed SUVmax differences of about +40% between
PSF + TOF and OSEM + TOF as well as between PSF
and OSEM. Again, differences increased with an increas-
ing number of iterations [16].
However, the observed inter-method differences re-
lated to PSF were significantly correlated with the le-
sions’ TBR and were significantly lower in lesions with a
low TBR. A recent study on FDG-PET phantom mea-
surements analyzed radial activity concentration profiles
of spheres filled with a solution of F18-FDG at three dif-
ferent SBR. It demonstrated that signal elevations at the
spheres’ boundaries (known as Gibbs artifacts [17]) oc-
curred only in PSF + TOF and PSF and only at medium
(6:1) and high (16:1) SBR. In analogy to the current re-
sults, this led to an artificially increased SBR and to the
observed deviations in quantitative parameters [13].The integration of TOF analysis resulted in SUVmax
differences comparable to those observed for additional
PSF (PSF + TOF vs. PSF, +10.4%; 3D-OSEM+ TOF vs.
3D-OSEM, +8.6%). However, these deviations were mea-
sured in lesions with a low TBR while SUV in high-
contrast lesions were significantly less affected by TOF.
These inverse findings of PSF and TOF may explain why
no correlation was observed for differences between
combined PSF + TOF and 3D-OSEM (non-PSF, non-
TOF) and the TBR. In other words, PSF + TOF increased
SUVmax across the entire range of the TBR when com-
pared to 3D-OSEM (correlation plot not shown). As a
consequence, a differentiated assessment of PSF + TOF
and PSF with regard to varying TBR is required. There
are scarce data on the independent influence of TOF
analysis on SUV in clinical lesions. In the abovemen-
tioned study, Akamatsu et al. reported SUVmax differ-
ences of only +2% between PSF + TOF and PSF as well
as between OSEM +TOF and OSEM, probably due to
relatively high TBR of the analyzed lesions. Nevertheless,
a TOF-related SUVmax increase was mainly observed in
lesions with low SUVmax [16]. Schaefferkoetter et al.
Figure 4 Interaction plots between the TBR and the lesion volume. Interaction plots of the lesions’ TBR and the lesion volume on relative
SUVmax differences between corresponding PSF and non-PSF algorithms (upper row) or TOF and non-TOF algorithms (lower row), respectively.
The TBR and the lesion volume were binarized by their respective median value. In general, an increased effect of the TBR on SUVmax differences
is observed in smaller lesions. This interaction between TBR and lesion volume is indicated by non-parallel courses of corresponding gray and
black dashed lines.
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foci which were artificially added to FDG-PET scans of
23 patients. The authors reported increasing SNR of
OSEM+ TOF, PSF, and PSF + TOF compared to OSEM.
In analogy to the current results, the relative SNR gain
of OSEM+TOF vs. OSEM was higher in lesions with
lower count rate (20,000 vs. 60,000 counts) [18]. Taniguchi
et al. performed phantom measurements (lesion diameter,
10 to 37 mm) and clinical studies in hepatic lesions (aver-
age diameter, 10.7 mm) to analyze the influence of PSF
and TOF on lesion contrast, coefficient of variation (CV)
of the background activity, as well as lesion SNR. Both
PSF and TOF independently increased liver lesion SNR
with the best tradeoff between lesion contrast and CV for
combined PSF + TOF. Furthermore, PSF + TOF reduced
the CV of the liver in overweight patients (>70 kg) to the
CV level in OSEM reconstructed data of normal-weight pa-
tients (<70 kg) [19]. That such differences in quantitativemeasures can also result in improved lesion detection was
shown by El Fakhri et al. who analyzed the influence of
TOF integration on detection rates in simulated liver
and lung lesions. TOF improved lesion detection over
non-TOF PET in both hepatic and pulmonary lesions
but showed the greatest advantage at low contrast
(contrast, 2.0:1 vs. 5.7:1) and in patients with higher
body mass index (BMI; >30 vs. <30) [20].
It is well known that the TBR is affected by the lesion
size due to partial volume effects which are more pro-
nounced in smaller lesions [21,22]. As we observed such
a positive correlation between the lesion volume and the
TBR, we included the TBR, the lesion volume, and their
interaction into GLMs. For PSF integration, the GLM
showed no association between SUVmax differences and
the lesion size whereas a highly significant association
with the TBR was observed. In addition, there was a sig-
nificant interaction between the TBR and the lesion
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related SUVmax differences depends on the lesion vol-
ume. Thus, we observed an increased impact of the TBR
in smaller lesions. Also, in TOF integration, the SUV-
max differences showed a significant association with
the TBR (PSF + TOF vs. PSF) or a tendency towards an
association (3D-OSEM+ TOF vs. 3D-OSEM). In com-
parison to PSF, a similar effect of the lesion volume can
be observed in the interaction plots. However, in GLM,
the interaction term showed no significance which may
be caused by a high variance of SUVmax differences in
combination with a small sample size. This dependency
of TOF-related effects on the lesion volume is in agree-
ment with previous studies showing that the impact of
TOF is especially relevant in small lesions [23,24].
SUVmax are commonly used for threshold-dependent
volume definition in a clinical setting. If the delineation
is strictly based on SUVmax (i.e., relative threshold with-
out background correction), these differences would also
implicate corresponding MTV deviations as reported
previously [12]. However, we refrained from volumetric
analyses as such delineation methods may not reflect the
clinical practice where more sophisticated algorithms
with background correction or manual MTV delineation
are required - especially in hepatic lesions [14,25,26].
Thus, the actual MTV deviations may be lower and less
dependent on the TBR than the current results on SUV-
max deviations suggest.
Nevertheless, these results underline that quantitative
analyses in radiotherapy planning, follow-up, or multi-
center studies can be distorted not only by different re-
construction settings but also when comparing lesions
located in different organs (e.g., lung and liver) or one
lesion with varying TBR measured over the course of
time. Depending on the lesions’ TBR, one must be aware
of SUVmax deviations mainly caused by PSF or TOF, re-
spectively. This may be particularly true for hepatic
lesions that feature a range of TBR in which both PSF-
and TOF-related effects are relevant.
The present study is limited by the retrospective inclu-
sion of only 15 patients with 28 lesions which may im-
pair an accurate interpretation of the data that were
characterized by relatively large IQRs.
Conclusions
Both PSF and TOF integration independently resulted in
substantially increased SUVmax in CRLM. However,
PSF- and TOF-related deviations showed an inverse cor-
relation with the lesions’ TBR. TOF showed the highest
SUVmax deviations in low-contrast lesions, whereas PSF
revealed a substantial effect on SUVmax in high-contrast
lesions. Although an interaction between the TBR and le-
sion volume was observed, these effects were still present
after adjustment for the lesion volume. Thus, quantitativeanalyses in radiotherapy planning, follow-up, or multicen-
ter studies can be distorted when comparing lesions lo-
cated in different organs or one lesion with varying TBR
measured over the course of time.
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